CTLA4 and neoplasm: We previously reported enhanced antitumor activity when APR-246 was combined with either anti-PD-1 alone or dual blockade of PD-1 and cytotoxic T-lymphocyte antigen 4 protein (CTLA-4) in multiple murine tumor types (Ghosh et al, 2022).